Type of information: Grant
Company: Metrion Biosciences (UK)
Investors: Innovate UK Biomedical Catalyst Feasibility Award scheme (UK)
Amount: £200 000
Funding type: grant
- The funding will be used to support further preclinical development activities to be undertaken on the portfolio of small molecule potassium inhibitors acquired by Metrion from Japan Tobacco, with the aim of delivering a ‘best in class’, orally bioavailable, small molecule potassium channel inhibitor for the safe and effective treatment of a range of autoimmune diseases. This project is the first of a series of potassium channel inhibitor programmes Metrion has planned, which are designed to deliver proof of concept data on immune-sparing drug candidates, for treatment of autoimmune and neurodegenerative diseases.
- • On February 5, 2018, Metrion Biosciences, the specialist ion channel contract research and drug discovery company, announced it has been awarded £200k funding under the Innovate UK Biomedical Catalyst Feasibility Award scheme.
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases